A Roche Holding AG (ROG) experimental drug called MetMab, used with another medicine, extended the lives of lung-cancer patients whose tumors had high levels of a protein known to trigger the disease and help it spread, a study found.
MetMab, which targets a gene called Met, was given in combination with Tarceva, another Roche medicine, to lung-cancer patients whose disease didn’t improve after other therapy. About half of lung tumors have high levels of Met.